We recently published a list of 12 Best Dow Stocks to Buy Right Now. In this article, we are going to take a look at where ...

We recently published an article titled Jim Cramer Discusses These 18 Stocks & President Trump’s $500 Billion AI Plan. In ...

Merck & Co. Inc. closed 29.03% below its 52-week high of $134.63, which the company reached on June 25th.

Merck & Co. and Eisai have to deal with the reality that yet another phase 3 trial of their combination of Keytruda and ...

We recently compiled a list of the 9 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where ...

In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against the other large-cap value stocks. Why is this Portfolio Manager Cautiously Optimistic? The market ...

Merck & Co. and Eisai reported mixed results from a late-stage study of the cancer drugs Keytruda and Lenvima in patients with certain types of gastroesophageal cancer.

Merck and Co. expects to launch an easier-to-administer version of its blockbuster cancer treatment Keytruda before the end ...

Ab&B Bio-Tech has joined the stacked roster of drug developers queuing up to go public in Hong Kong, filing the paperwork for ...

The unsuccessful Phase III results are the latest to suggest that the blockbuster cancer drug is finally bumping up against ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...